Establishing metrics of clinically meaningful change for treating knee osteoarthritis with a combination of autologous orthobiologics.

ABSTRACT: Autologous bone marrow concentrate (BMC), platelet-rich plasma (PRP), and platelet lysate (PL) have emerged as promising orthobiologic treatment options for knee osteoarthritis (OA). The present observational study reports minimal clinically important difference (MCID) and substantial clinical benefit (SCB) values for several patient-reported outcome measures (PROMs) used to monitor changes in joint pain and function following percutaneous treatment of knee OA with a combination of BMC and platelet products (n = 295 knees). Distribution-based approaches were used to determine 12-month MCID values for the International Knee Documentation Committee (IKDC) subjective, Lower Extremity Functional Scale (LEFS), Numeric Pain Scale (NPS), and modified Single Assessment Numeric Evaluation (SANE) sc

SUBMITTER: Centeno CJ 

PROVIDER: S-EPMC11871318 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature